Urine-based diagnostics Opportunity to position INDICAID and PHASIFY as convenient, at-home or point-of-care solutions for early cancer and infectious disease screening, appealing to healthcare providers seeking rapid, non-invasive testing options and to employers or insurers aiming to support preventive health.

Series A momentum Leverage the recent $34M Series A to engage strategic investors, potential channel partners, and healthcare systems interested in scaling urine-based diagnostics and accelerated screening tools, highlighting growth trajectory and validated demand.

Global footprint Sales strategy can target cross-border opportunities across Hong Kong, the United States (Southern California), and China’s Greater Bay Area by offering interoperable lab services (PHASIFY Lab) and expanded distribution for INDICAID tests in regional markets with varying regulatory paths.

Proprietary edge Position PHASIFY technology as a differentiator to healthcare buyers looking for higher sensitivity and faster turnaround in molecular detection, enabling bundled solutions with PHASIFY viral RNA extraction kits for end-to-end rapid diagnostics.

Healthcare partnerships Target collaborations with hospitals, clinics, and public health programs for early screening, diagnostics, and monitoring workflows, including integration with existing lab infrastructure and potential reimbursement discussions to drive adoption of the screening ecosystem.